The competitive standard in the obesity treatment market is shifting from simple weight loss to reducing body fat while preserving muscle as much as possible. Accordingly, securities firms分析 that business opportunities for InBody, a specialized body composition analyzer company, may expand.

IBK Investment & Securities initiated coverage of InBody on the 27th with an investment opinion of 'Buy' and a target price of 81,000 won. Considering that InBody's closing price the previous day was 60,300 won, this implies approximately 34% upside potential.

The 'Quality of Weight Loss' as a Competitive Standard

Yoo Chang-geun, a researcher at IBK Investment & Securities, analyzed that in the recent obesity treatment market, not only how much weight is lost but also how much muscle mass can be maintained during the weight loss process has become an important evaluation criterion. He particularly noted that the next-generation obesity treatment being developed by Hanmi Pharmaceutical is being developed in a direction that minimizes muscle loss while enhancing body fat reduction effects.

The explanation is that as the goal of obesity treatment expands from simple weight reduction to the 'quality of weight loss,' the need for body composition analysis, which can specifically confirm changes in a patient's muscle and fat, will also grow.

Beyond Gyms to Medical Institutions... Expectations of Forward Market Expansion

Accordingly, it has been suggested that InBody's forward market may also broaden from its existing focus on gyms and fitness centers to medical institutions and the obesity treatment field. This is because measuring weight alone makes it difficult to distinguish changes in muscle mass and body fat during the treatment process, so body composition analyzers could be utilized as supplementary management tools in the obesity treatment process.

IBK Investment & Securities projected that as the next-generation obesity treatment market grows, the need to continuously measure patients' body composition before and after treatment will increase. Researcher Yoo stated, "As the quality of weight loss becomes more important than simple weight reduction, the expansion of demand for body composition analyzers is inevitable," suggesting InBody's potential to benefit.

InBody is a company with body composition analyzers as its main product, expanding its business not only in Korea but also in overseas markets. If obesity treatments in the future develop beyond weight loss to evaluating muscle preservation and body fat management, whether the scope of use for body composition measurement equipment widens further into medical settings is expected to act as a key variable for earnings.

However, the speed at which the expansion of the obesity treatment market translates into actual increased sales of InBody products, and whether body composition analyzers become established as standard management equipment in medical institutions, remain to be confirmed.

[Stock prices may exhibit increased volatility depending on corporate earnings, industry conditions, merger terms, market supply and demand, and other factors. Securities firms' analyses and forecasts may differ from actual future results and do not guarantee returns on specific stocks. Before making investment decisions, it is necessary to comprehensively review the company's official disclosures, financial condition, and business progress. This article is not intended to recommend the purchase or sale of specific stocks. This article was written with AI assistance.]